Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cephalon, a biopharmaceutical company, has announced that the FDA has approved Treanda for injection for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
Subscribe to our email newsletter
According to the company, the data supporting the FDA approval show that Treanda is effective, has a tolerable side effect profile in patients with indolent non-Hodgkin’s lymphoma (NHL) and that treatment results in a high durable response rate.
The FDA approval is supported by a pivotal study which demonstrated that patients had a high response rate to treatment with Treanda and these responses to the treatment were durable.
Lesley Russell, executive vice president and chief medical officer of Cephalon, said: “We are excited about this second FDA approval for Treanda in 2008. This approval of Treanda for indolent NHL is a significant milestone in our development of a diverse oncology portfolio of products that improve patient outcomes.”